Filter posts

XOMA to initiate Phase 2 program for Type 2 Diabetes and Cardiovascular Disease

XOMA Ltd. (Nasdaq:XOMA) announced plans for the Phase 2 clinical development of its anti-inflammatory drug …

U.S. Navy to fund Vical's H1N1 vaccine

The U.S. Navy has awarded a contract for $1.25 million to Vical Incorporated (Nasdaq:VICL) for …

Hana Biosciences’ clinical trial agreement with the National Cancer Institute

Hana Biosciences (OTCBB:HNAB) announced a Clinical Trial Agreement with the Center for Cancer Research (CCR) …

Intarcia presents positive results of Type 2 Diabetes study

Intarcia Therapeutics, Inc. presented final results from its Phase 1b clinical study of ITCA 650 …

MDRNA patent allowance for siRNA

MDRNA, Inc. (NASDAQ: MRNA) announced that the U.S. Patent and Trademark Office (USPTO) has issued …

Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. complete merger

Raptor Pharmaceuticals Corp. (“Raptor”) (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. (“TorreyPines”) (Nasdaq: TPTX) …

LifeCycle Pharma announces Phase 2 results for liver transplant patients study

LifeCycle Pharma A/S (CSE:LCP) announced positive results from a 12 month extension phase of the …

RegeneRx’s TB4 shows functional recovery in MS animal model

RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) announces significant improvement in neurological functional recovery after TB4 treatment …

Novelos announces $1 million NIH Grant

Novelos Therapeutics, Inc. (OTCBB: NVLT) was awarded a $950,371 competitive grant by the National Institutes …

Positive Results in Plague Study

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced results from a primate study …